Clinical Trial Update: Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial [Phase 2]

View source ↗

Summary

Phase 2, single-arm trial in China evaluating neoadjuvant stereotactic body radiotherapy with sequential iparomlimab and tuvonralimab (QL1706) plus chemotherapy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Jiangsu Cancer Institute & Hospital | Conditions: NSCLC, NSCLC (Non-small Cell Lung Cancer) | Phase 2 | Status: NOT_YET_RECRUITING